{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:24:57Z","timestamp":1793805897384,"version":"4.6.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jocn.2026.112169","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T19:39:17Z","timestamp":1782329957000},"page":"112169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcomes of ferroptosis-inducing agents in glioblastoma: A systematic review of clinical trials"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5382-3123","authenticated-orcid":false,"given":"Younseo","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke S.","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-5751","authenticated-orcid":false,"given":"Koki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-2592","authenticated-orcid":false,"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-1297","authenticated-orcid":false,"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2026.112169_b0005","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112169_b0020","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00701-023-05544-3","article-title":"Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics","volume":"165","author":"Chehade","year":"2023","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.jocn.2026.112169_b0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072116","article-title":"Mechanisms of resistance and current treatment options for glioblastoma multiforme (GBM)","volume":"15","author":"Yalamarty","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jocn.2026.112169_b0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174279","article-title":"Recurrent glioblastoma: a review of the treatment options","volume":"15","author":"Vaz-Salgado","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jocn.2026.112169_b0035","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jocn.2026.112169_b0040","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","article-title":"The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions","volume":"42","author":"Lei","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jocn.2026.112169_b0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","article-title":"A guide to cell death pathways","volume":"25","author":"Yuan","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jocn.2026.112169_b0050","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jocn.2026.112169_b0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jocn.2026.112169_b0060","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.974156","article-title":"Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges","volume":"9","author":"Zhuo","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jocn.2026.112169_b0065","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9107857","article-title":"A ferroptosis-related prognostic risk score model to predict clinical significance and immunogenic characteristics in glioblastoma multiforme","volume":"2021","author":"Xiao","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.jocn.2026.112169_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-016-2742-x","article-title":"Sulfasalazine intensifies temozolomide cytotoxicity in human glioblastoma cells","volume":"418","author":"Ignarro","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jocn.2026.112169_b0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41374-022-00779-7","article-title":"Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain","volume":"102","author":"Yang","year":"2022","journal-title":"Lab Invest"},{"key":"10.1016\/j.jocn.2026.112169_b0080","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1038\/onc.2015.60","article-title":"Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion","volume":"34","author":"Sleire","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.jocn.2026.112169_b0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1021\/acschembio.9b00939","article-title":"Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers","volume":"15","author":"Ye","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jocn.2026.112169_b0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting ferroptosis to iron out cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jocn.2026.112169_b0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41420-025-02744-x","article-title":"Harnessing ferroptosis to transform glioblastoma therapy and surmount treatment resistance","volume":"11","author":"Singh","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jocn.2026.112169_b0100","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112169_b0105","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112169_b0110","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112169_b0115","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/neuonc\/nor145","article-title":"Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma","volume":"13","author":"Nabors","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijrobp.2012.04.017","article-title":"A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas","volume":"85","author":"Den","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jocn.2026.112169_b0125","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jocn.2026.112169_b0130","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1002\/cncr.25275","article-title":"Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme","volume":"116","author":"Hainsworth","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2026.112169_b0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11060-010-0217-6","article-title":"Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma","volume":"101","author":"Reardon","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2026.112169_b0140","first-page":"3487","article-title":"Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study","volume":"33","author":"Zustovich","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jocn.2026.112169_b0145","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nos264","article-title":"Phase I\/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: north American Brain Tumor Consortium study 05-02","volume":"14","author":"Lee","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0150","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/cncr.31219","article-title":"Phase 1\/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study\/Alliance N0572","volume":"124","author":"Schiff","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2026.112169_b0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/neuonc\/nos322","article-title":"NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme","volume":"15","author":"Peereboom","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0160","article-title":"Phase I\/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02","volume":"2","author":"Chen","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.jocn.2026.112169_b0165","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1158\/1078-0432.CCR-13-0708","article-title":"Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial","volume":"19","author":"Galanis","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2026.112169_b0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-017-2624-4","article-title":"Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02","volume":"136","author":"Nghiemphu","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2026.112169_b0175","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/1471-2407-9-372","article-title":"Early termination of ISRCTN45828668, a phase 1\/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults","volume":"9","author":"Robe","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jocn.2026.112169_b0180","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000421-199812000-00010","article-title":"A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme","volume":"21","author":"Larner","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0185","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0190","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0195","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0200","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10637-005-2910-4","article-title":"Phase I\/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial","volume":"23","author":"Galanis","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jocn.2026.112169_b0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-008-9749-4","article-title":"Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results","volume":"92","author":"Santisteban","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2026.112169_b0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1215\/S1152851703000218","article-title":"Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11","volume":"6","author":"Batchelor","year":"2004","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1215\/S1152851703000353","article-title":"Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas","volume":"7","author":"Grossman","year":"2005","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0220","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.2001.19.13.3260","article-title":"Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas","volume":"19","author":"Grossman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0225","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0230","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0235","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jocn.2026.112169_b0240","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12967-024-05301-9","article-title":"The tumour microenvironment, treatment resistance and recurrence in glioblastoma","volume":"22","author":"White","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.jocn.2026.112169_b0245","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11060-022-04039-y","article-title":"Analysis of factors leading to early termination in glioblastoma-related clinical trials","volume":"158","author":"Shah","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2026.112169_b0250","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0255","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jocn.2026.112169_b0260","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","article-title":"Management of sorafenib-related adverse events: a clinician's perspective","volume":"41","author":"Brose","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1215\/15228517-2006-024","article-title":"The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas","volume":"9","author":"Gerber","year":"2007","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jocn.2026.112169_b0270","first-page":"147","article-title":"ACSL4 suppresses glioma cells proliferation via activating ferroptosis","volume":"43","author":"Cheng","year":"2020","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jocn.2026.112169_b0275","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-03-0392","article-title":"In vitro and in vivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas","volume":"10","author":"Robe","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocn.2026.112169_b0280","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd1112","article-title":"Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors","volume":"2","author":"Tobert","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jocn.2026.112169_b0285","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocn.2026.112169_b0290","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jocn.2026.112169_b0295","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41419-021-03998-w","article-title":"Sorafenib fails to trigger ferroptosis across a wide range of cancer cell lines","volume":"12","author":"Zheng","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jocn.2026.112169_b0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0028-3886.128280","article-title":"Sulfasalazine and temozolomide with radiation therapy for newly diagnosed glioblastoma","volume":"62","author":"Takeuchi","year":"2014","journal-title":"Neurol India"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826003206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826003206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:25:22Z","timestamp":1793802322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826003206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":60,"alternative-id":["S0967586826003206"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112169","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes of ferroptosis-inducing agents in glioblastoma: A systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112169","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112169"}}